Loading...
Exemestane for Breast Cancer Prevention: A Critical Shift?
The Mammary Prevention 3 (MAP.3) placebo-controlled randomized trial in 4,560 high-risk postmenopausal women showed a 65% reduction in invasive breast cancer with the use of exemestane at 35 months median follow-up. Few differences in adverse events were observed between the arms, suggesting a promi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2012
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3354700/ https://ncbi.nlm.nih.gov/pubmed/22585166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-11-0248 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|